isoflurane (Rx)

Brand and Other Names:Forane
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

inhalation solution

  • 100mL
  • 250mL

Anesthesia Induction & Maintenance

Use calibrated vaporizer

Induction: 1.5-3% can produce surgical anesthesia in 7-10 minutes

Maintenance: 1-2.5% with nitrous oxide

Additional 0.5-1% may be needed if given with oxygen alone

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and isoflurane

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.
            Previous
            Next:

            Adverse Effects

            1-10%

            Nausea

            Vomiting

            Shivering

            <1%

            Dose-dependent hypotension

            Arrhythmias

            Malignant hyperthermia (rare)

            Elevations in white blood count

            May decrease creatinine and increase BUN

            Ileus, severe (fatal)

            Hepatic dysfunction (postoperative period) (rare)

            Respiratory depression may occur (rare)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to isoflurane & halogenated agents

            Genetic susceptibility to malignant hyperthermia

            Patients in whom general anesthesia contraindicated

            History of confirmed hepatitis due to a halogenated inhalational anesthetic or a history of unexplained moderate to severe hepatic dysfunction (eg, jaundice associated with fever and/or eosinophilia) after anesthesia with isoflurane or other halogenated inhalational anesthetics

            Cautions

            Caution in coronary heart disease

            May decrease renal and hepatic blood flow

            Postoperative hepatic dysfunction and hepatitis reported

            Adequate data have not been developed to establish its application in obstetrical anesthesia

            Should not be used as a sole agent of induction in patients with ventricular dysfunction

            Therapy should only be administered in an adequately equipped anesthetizing environment by those who are familiar with the pharmacology of the drug and qualified by training and experience to manage the anesthetized patient

            All patients receiving the drug should be continually monitored (eg, monitoring of the electrocardiogram, blood pressure, oxygen saturation, and end tidal CO2)

            The drug is a profound respiratory depressant; excessive respiratory depression may be related to depth of anesthesia and respond to decreasing the inspired concentration of isoflurane

            The depressant effect is accentuated by concurrent use of opioids and other respiratory depressants; respiration should be closely monitored and assisted or controlled ventilation employed when necessary

            With the exception of neonates, isoflurane MAC decreases with increasing age

            QTc prolongation, with rare instances of torsade de pointes, reported; monitor QT interval when administering the drug to susceptible patients

            Regardless of the anesthetics employed, maintenance of normal hemodynamics is important to the avoidance of myocardial ischemia in patients with coronary artery disease

            Isoflurane can cause dose-dependent coronary vasodilation and has been shown to divert blood from collateral-dependent myocardium to normally perfused areas in an animal model (“coronary steal”); monitor for signs of inadequate myocardial perfusion via hemodynamic monitors (eg, ECG, blood pressure) during administration; consider additional cardiac monitoring in patients with known coronary artery disease, as clinically necessary

            Isoflurane causes a dose-dependent reduction in systemic vascular resistance and blood pressure; particular care must be taken when selecting the dosage for patients who are hypovolemic, hypotensive, or otherwise hemodynamically compromised, eg, due to concomitant medications

            Increased blood loss comparable to that seen with halothane observed in patients undergoing abortions

            Allergic-type hypersensitivity reactions, including anaphylaxis, reported with therapy; manifestations of such reactions have included hypotension, rash, difficulty breathing and cardiovascular collapse

            The drug markedly increases cerebral blood flow at deeper levels of anesthesia to produce a transient increase in intracranial pressure; in patients with or at risk for elevations of intracranial pressure (ICP), administer isoflurane in conjunction with ICP- reducing strategies, as clinically appropriate

            The color indicator of most CO2 absorbents does not necessarily change as a result of desiccation; therefore, the lack of significant color change should not be taken as assurance of adequate hydration of the CO2 absorbent material; CO2 absorbents should be replaced routinely regardless of the state of color indicator following current manufacturer’s guidelines for use of anesthesiology equipment

            Reactions reported following occupational exposure to the drug include dyspnea, bronchospasm, stridor, cough, dizziness, paresthesia, hepatic reactions, flushing rash, contact dermatitis, erythema, periorbital edema, eye irritation, conjunctival hyperemia, and headache

            Hepatic reactions

            • Cases of mild, moderate and severe postoperative hepatic dysfunction or hepatitis with or without jaundice, including fatal hepatic necrosis and hepatic failure, reported
            • Such reactions can represent hypersensitivity hepatitis, a known risk of exposure to halogenated anesthetics, including isoflurane
            • As with other halogenated anesthetic agents, the drug may cause sensitivity hepatitis in patients sensitized by previous exposure to halogenated anesthetics
            • Clinical judgment should be exercised when isoflurane the drug is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction
            • As with all halogenated anesthetics, repeated anesthetics within a short period of time may result in increased effects, particularly in patients with underlying hepatic conditions, or additive effects in patients treated with drugs known to cause hepatic dysfunction
            • Evaluate the need for repeated exposure in each individual patient and adjust the dose of isoflurane based on signs and symptoms of adequate depth of anesthesia if repeated exposure in a short period of time is clinically indicated

            Malignant hyperthermia

            • In susceptible individuals, isoflurane anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia; fatal outcomes of malignant hyperthermia have been reported
            • Risk of developing malignant hyperthermia increases with concomitant administration of succinylcholine and volatile anesthetic agents; therapy can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants
            • Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia, hypercapnia, muscle rigidity (eg, jaw muscle spasm), tachycardia (eg, particularly that unresponsive to deepening anesthesia or analgesic medication administration), tachypnea, cyanosis, arrhythmias, hypovolemia, and hemodynamic instability; skin mottling, coagulopathies, and renal failure may occur later in the course of the hypermetabolic process
            • An increase in overall metabolism may be reflected in an elevated temperature, (which may rise rapidly early or late in the case, but usually is not the first sign of augmented metabolism) and increased usage of the CO2 absorption system (hot canister)
            • PaO2 and pH may decrease, and hyperkalemia and a base deficit may appear; treatment includes discontinuance of triggering agents (eg, isoflurane), administration of intravenous dantrolene sodium, and application of supportive therapy
            • Successful treatment of malignant hyperthermia depends on early recognition of clinical signs; if malignant hyperthermia suspected, discontinue all triggering agents (eg, volatile anesthetic agents and succinylcholine), administer intravenous dantrolene sodium, and initiate supportive therapies
            • Consult prescribing information for intravenous dantrolene sodium for additional information on patient management
            • Supportive therapies include administration of supplemental oxygen and respiratory support based on clinical need, maintenance of hemodynamic stability and adequate urinary output, management of fluid and electrolyte balance, correction of acid-base derangements, and institution of measures to control rising temperature
            • Renal failure may appear later, and urine flow should be sustained if possible; fatal outcome of malignant hyperthermia has been reported with isoflurane

            Pediatric use

            • During the induction of anesthesia, saliva flow and tracheobronchial secretion can increase and can be the cause of larynogospasm, particularly in children

            Perioperative Hyperkalemia

            • Inhaled anesthetics associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients postoperatively
            • Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable
            • Concomitant use of succinylcholine has been associated with most, but not all, of these cases
            • Elevated serum creatinine kinase levels and, in some cases, changes in urine consistent with myoglobinuria observed
            • Despite similar presentation to malignant hyperthermia, none of affected patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state
            • Early and aggressive intervention to treat hyperkalemia and resistant arrhythmias recommended
            • Evaluation for latent neuromuscular disease recomended

            General anesthetics and sedation drugs in young children and pregnant women

            • Brain development
              • Prolonged or repeated exposure may result in negative effects on fetal or young children’s brain development
              • Caution with use during surgeries or procedures in children younger than 3 yr or in pregnant women during their third trimester
              • Assess the risk:benefit ratio in these populations, especially for prolonged procedures (ie, >3 hr) or multiple procedures
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            There are no adequate and well-controlled studies in pregnant women; in animal reproduction studies, embryofetal toxicity was noted in pregnant mice exposed to 0.075% (increased post implantation losses) and 0.3% isoflurane (increased post implantation losses and decreased live- birth index) during organogenesis

            Lactation

            Due to insufficient information regarding the excretion of isoflurane in human milk, the potential risks and benefits for each specific patient should be carefully considered before isoflurane is administered to nursing women

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Volatile liquid inhalation anesthetic

            Pharmacokinetics

            Onset: Rapid (7-10 min)

            Duration: Short (depends on blood concentration)

            Minimum Alveolar Conc: 1.3%

            Metabolism: Liver (0.2%)

            Pharmacogenomics

            Increased incidence of malignant hyperthermia with use of volatile anesthetics or depolarizing neuromuscular blockers in patients with gene mutations in ryanodine receptor (RYR1) or calcium channel alpha (1S)- subunit gene (CACNA1S)

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            isoflurane inhalation
            -
            99.9 % liquid
            isoflurane inhalation
            -
            99.9 % liquid

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            isoflurane inhalation

            NO MONOGRAPH AVAILABLE AT THIS TIME

            USES: Consult your pharmacist.

            HOW TO USE: Consult your pharmacist.

            SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Consult your pharmacist.

            DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

            NOTES: No monograph available at this time.

            MISSED DOSE: Consult your pharmacist.

            STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

            Information last revised July 2016. Copyright(c) 2022 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.